Empowered Patient Podcast

Greg Duncan, CEO, Celtaxsys tells us about the work the company is doing to help reduce pulmonary exacerbations in patients with cystic fibrosis. Cystic fibrosis is a rare genetic life-threatening disease that affects over 70,000 people worldwide. Pulmonary exacerbations are sudden, severe respiratory events that ultimately lead to lung function decline. Celtaxsys’ lead candidate, once-daily anti-inflammatory acebilustat, which the company is currently progressing to Phase 3 development, has the potential to prevent lung function decline by reducing the frequency of pulmonary exacerbations. #cysticfibrosis #CFresearch #RareDisease #CFAware #acebilustat Celtaxsys.com